These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 19329547)

  • 21. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
    Coghill DR; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson CS; Civil R; Dauphin M; Higgins N; Lyne A; Gasior M; Squires LA
    J Am Acad Child Adolesc Psychiatry; 2014 Jun; 53(6):647-657.e1. PubMed ID: 24839883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder.
    Faraone SV
    Expert Opin Pharmacother; 2008 Jun; 9(9):1565-74. PubMed ID: 18518785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.
    Findling RL; Ginsberg LD; Jain R; Gao J
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):649-62. PubMed ID: 20035583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of lisdexamfetamine dimesylate for the treatment of ADHD.
    Childress AC; Sallee FR
    Expert Rev Neurother; 2012 Jan; 12(1):13-26. PubMed ID: 22243042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.
    Martin P; Dirks B; Gertsik L; Walling D; Stevenson A; Corcoran M; Raychaudhuri A; Ermer J
    J Clin Psychopharmacol; 2014 Dec; 34(6):682-9. PubMed ID: 25310201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Wigal T; Brams M; Gasior M; Gao J; Giblin J
    Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug.
    Hutson PH; Pennick M; Secker R
    Neuropharmacology; 2014 Dec; 87():41-50. PubMed ID: 24594478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.
    Roesch B; Corcoran ME; Fetterolf J; Haffey M; Martin P; Preston P; Purkayastha J; Wang P; Ermer J
    Drugs R D; 2013 Jun; 13(2):119-28. PubMed ID: 23615868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lisdexamfetamine: chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder.
    Ward K; Citrome L
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):229-238. PubMed ID: 29258368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.
    Lopez FA; Ginsberg LD; Arnold V
    Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challenges.
    López FA; Leroux JR
    Atten Defic Hyperact Disord; 2013 Sep; 5(3):249-65. PubMed ID: 23564273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults.
    Faraone SV
    J Atten Disord; 2012 Feb; 16(2):128-37. PubMed ID: 20837983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events in medication treatment-naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate.
    Wigal SB; Wong AA; Jun A; Stehli A; Steinberg-Epstein R; Lerner MA
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):149-56. PubMed ID: 22372513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
    Haffey MB; Buckwalter M; Zhang P; Homolka R; Martin P; Lasseter KC; Ermer JC
    Postgrad Med; 2009 Sep; 121(5):11-9. PubMed ID: 19820270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trial.
    Mooney ME; Herin DV; Specker S; Babb D; Levin FR; Grabowski J
    Drug Alcohol Depend; 2015 Aug; 153():94-103. PubMed ID: 26116930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.
    Ermer JC; Dennis K; Haffey MB; Doll WJ; Sandefer EP; Buckwalter M; Page RC; Diehl B; Martin PT
    Clin Drug Investig; 2011; 31(6):357-70. PubMed ID: 21539403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink.
    Ermer J; Corcoran M; Lasseter K; Martin PT
    Ther Drug Monit; 2016 Dec; 38(6):769-776. PubMed ID: 27661399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duration of effect of oral long-acting stimulant medications for ADHD throughout the day.
    Brams M; Moon E; Pucci M; López FA
    Curr Med Res Opin; 2010 Aug; 26(8):1809-25. PubMed ID: 20491612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.